PD-L1 CPS ≥1 is required for pembrolizumab in persistent/recurrent/metastatic cervical ca...
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | BMA-PDL1-CPS-CERVICAL |
|---|---|
| Tipo | Relevância terapêutica |
| Estado | reviewed 2026-05-07 | actionability review required |
| Doenças | DIS-CERVICAL |
| Fontes | SRC-ESMO-CERVICAL-2024 SRC-KEYNOTE-826-COLOMBO-2021 SRC-NCCN-CERVICAL-2025 |
Fatos de ação
| Biomarcador | BIO-PDL1-CPS |
|---|---|
| Doença | DIS-CERVICAL |
| Nível ESCAT | IA |
| Combinações recomendadas | pembrolizumab + paclitaxel + cisplatin/carboplatin ± bevacizumab (CPS≥1 1L per SRC-NCCN-CERVICAL-2025, SRC-ESMO-CERVICAL-2024, SRC-KEYNOTE-826-COLOMBO-2021) |
| Resumo das provas | PD-L1 CPS ≥1 is required for pembrolizumab in persistent/recurrent/metastatic cervical cancer (KEYNOTE-826): pembrolizumab + paclitaxel + cisplatin/carboplatin ± bevacizumab 1L (CPS≥1 mOS 28.6 mo vs 16.5 mo, HR 0.64). FDA-approved 2021. Testing by IHC 22C3 pharmDx. Threshold-gated indication selection performed by the algorithm layer (IND-CERVICAL-METASTATIC-1L-PEMBRO-CHEMO-BEV); this BMA entry surfaces ESCAT context only. |
Notas
Variant_qualifier null — CPS≥1 threshold gating enforced by indication layer. KEYNOTE-826 source stub ingested (SRC-KEYNOTE-826-COLOMBO-2021). ESCAT IA confirmed by FDA approval and NCCN Category 1.
Usado por
Não há referências reversas encontradas no corpus YAML.